Category 1 requirements for products that undergo a tailored CDR review have been revised. Submissions for new combination products (funded ... Read More
CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed ... Read More
Effective February 9, 2015 and until this process is transitioned to the pan-Canadian Pharmaceutical Alliance (pCPA) office, Saskatchewan will serve ... Read More